Literature DB >> 8897061

Induction of thrombolysis and prevention of thrombus formation by local drug delivery with a double-occlusion balloon catheter.

T Tomaru1, Y Fujimori, F Nakamura, N Aoki, Y Sakamoto, K Kawai, M Omata, Y Uchida.   

Abstract

The efficacy of the local delivery of an antithrombotic drug in preventing thrombosis and enabling thrombolysis was investigated in 29 dogs. An antithrombotic drug (heparin, 25 U/kg), or an antithrombin (argatroban, 0.05 mg/kg) was infused into injured canine iliac arteries, using a double-occlusion balloon catheter, and the preventive effect of the drug was evaluated. Local delivery of low-dose tissue-type plasminogen activator (t-PA; Tisokinase, 50,000 U; Kowa, Nagoya and Asahi Chemical Industries, Fuji, Japan) into thrombosed canine iliac arteries, using the same catheter, or intravenous infusion of low-dose or high-dose t-PA (30,000 U/kg) was also performed. Angiographically, stenotic thrombosis was 2% by local delivery of argatroban and 7% by local delivery of heparin (P < 0.01 vs each control; 47% and 51% respectively). Thrombotic stenosis, as observed by angiography, decreased from 91% to 9% after local delivery of t-PA, and from 94% to 52% in controls. Local delivery of t-PA effectively reduced the thrombus size (P < 0.01 vs control). After systemic intravenous delivery of low-dose t-PA, no reduction of residual thrombotic stenosis, was observed. Reduction of residual thrombotic stenosis after intravenous delivery of high-dose t-PA, was similar to that achieved by local delivery of the drug. Angioscopy demonstrated a similar trend. High-dose drug delivery reduced systemic coagulability. Local delivery of an antithrombotic drug, using a double-occlusion balloon catheter, effectively prevented thrombus formation, and local delivery of t-PA induced thrombolysis without exerting a significant influence on coagulability.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897061     DOI: 10.1007/bf01745170

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  27 in total

1.  Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes.

Authors:  K Mizuno; K Satomura; A Miyamoto; K Arakawa; T Shibuya; T Arai; A Kurita; H Nakamura; J A Ambrose
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

Review 2.  Reinfarction, recurrent angina, and reocclusion after thrombolytic therapy.

Authors:  D H Schaer; A M Ross; A G Wasserman
Journal:  Circulation       Date:  1987-08       Impact factor: 29.690

3.  Percutaneous transluminal coronary angioplasty in patients with intracoronary thrombus.

Authors:  U Deligonul; G I Gabliani; D G Caralis; M J Kern; M G Vandormael
Journal:  Am J Cardiol       Date:  1988-09-01       Impact factor: 2.778

Review 4.  After coronary thrombolysis and reperfusion, what next?

Authors:  N U Bang; O G Wilhelm; M D Clayman
Journal:  J Am Coll Cardiol       Date:  1989-10       Impact factor: 24.094

5.  Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.

Authors:  M Mirshahi; J Soria; C Soria; R Faivre; H Lu; M Courtney; C Roitsch; D Tripier; J P Caen
Journal:  Blood       Date:  1989-08-15       Impact factor: 22.113

6.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

7.  Local treatment with antithrombotic drugs can prevent thrombus formation: an angioscopic and angiographic study.

Authors:  T Tomaru; F Nakamura; Y Fujimori; M Omata; S Kawai; R Okada; Y Murata; Y Uchida
Journal:  J Am Coll Cardiol       Date:  1995-11-01       Impact factor: 24.094

8.  Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.

Authors:  R M Lidón; P Théroux; M Juneau; B Adelman; J Maraganore
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

9.  Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. In vitro, in vivo, and clinical studies.

Authors:  J F Mitchel; D B Fram; D F Palme; R Foster; J A Hirst; M A Azrin; L M Bow; A M Eldin; D D Waters; R G McKay
Journal:  Circulation       Date:  1995-02-01       Impact factor: 29.690

10.  Coronary angioscopy in patients with unstable angina pectoris.

Authors:  C T Sherman; F Litvack; W Grundfest; M Lee; A Hickey; A Chaux; R Kass; C Blanche; J Matloff; L Morgenstern
Journal:  N Engl J Med       Date:  1986-10-09       Impact factor: 91.245

View more
  2 in total

1.  Routine coronary angiographic follow-up and subsequent revascularization in patients with acute myocardial infarction.

Authors:  Katsunori Shimada; Hiroshi Kasanuki; Nobuhisa Hagiwara; Hiroshi Ogawa; Naohito Yamaguchi
Journal:  Heart Vessels       Date:  2008-11-27       Impact factor: 2.037

2.  2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.

Authors:  Claire R Sharp; Marie-Claude Blais; Corrin J Boyd; Benjamin M Brainard; Daniel L Chan; Armelle de Laforcade; Robert Goggs; Julien Guillaumin; Alex Lynch; Erin Mays; Duana McBride; Tommaso Rosati; Elizabeth A Rozanski
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2022-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.